LBRX

SEC source: 0002150267-26-000005 · form4-10132026_041001.xml · derivative · entry 1

Kozauer Susan Gani · CIK 0002150267 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2036-10-08

F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on September 14, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001746372-26-000007 · form4-10132026_041004.xml · derivative · entry 1

Miller Joseph M · CIK 0001746372 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2036-10-08

F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on September 2, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001193125-26-331058 · ownership.xml · derivative · entry 1

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 664,649

Underlying: Common Stock · 286,205 shares

Expires not disclosed

F1 · derivative.exercise_date: The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire.

F2 · derivative.exercise_date: Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock.

F1 · derivative.expiration_date: The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire.

F2 · derivative.expiration_date: Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock.

F3 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0001992908-26-000011 · form4-06052026_090641.xml · derivative · entry 1

Lenz Robert A. · CIK 0001992908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2036-06-02

F1 · shares: Includes an option award for 2,500 shares pursuant to the Issuer's non-employee director compensation policy which represents a prorated annual grant for the previous year.

F2 · derivative.exercise_date: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001813937-26-000003 · form4-06052026_090647.xml · derivative · entry 1

Kane William P Jr · CIK 0001813937 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001187308-26-000002 · form4-06052026_100631.xml · derivative · entry 1

RUFFOLO ROBERT R · CIK 0001187308 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001609805-26-000003 · form4-06052026_090603.xml · derivative · entry 1

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0002031342-26-000002 · form4-06052026_090613.xml · derivative · entry 1

Luse Rebecca · CIK 0002031342 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001771213-26-000002 · form4-06052026_090613.xml · derivative · entry 1

Hemrajani Rekha · CIK 0001771213 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001533228-26-000006 · form4-06052026_090631.xml · derivative · entry 1

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001992908-26-000007 · form4-03102026_080331.xml · derivative · entry 1

Lenz Robert A. · CIK 0001992908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-03-05

F1 · derivative.exercise_date: The shares subject to the option award shall vest in three (3) equal annual installments on March 6, 2027, March 6, 2028 and March 6, 2029, subject to the Reporting Person's continuous service through each such date.

SEC source: 0001193125-26-044776 · ownership.xml · derivative · entry 2

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Special Opportunities Fund, LP · CIK 0002077950 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Deep Track Special Opportunities Fund, LP

Disclosed balance after: 93,925

Underlying: Common Stock · 93,925 shares

Expires not disclosed

F1 · derivative.exercise_date: The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire.

F2 · derivative.exercise_date: Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock.

F1 · derivative.expiration_date: The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire.

F2 · derivative.expiration_date: Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock.

F4 · ownership.nature: Represents securities held by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP is the investment manager of Deep Track Special Opportunities Fund LP. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0001193125-26-044776 · ownership.xml · derivative · entry 1

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Special Opportunities Fund, LP · CIK 0002077950 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 378,444

Underlying: Common Stock · 378,444 shares

Expires not disclosed

F1 · derivative.exercise_date: The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire.

F2 · derivative.exercise_date: Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock.

F1 · derivative.expiration_date: The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire.

F2 · derivative.expiration_date: Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock.

F3 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0002095250-25-000006 · form4-12112025_041206.xml · derivative · entry 1

Pai Panandiker Kaya Kamlesh · CIK 0002095250 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,000

Underlying: Common Stock · 195,000 shares

Expires 2035-12-09

F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on November 10, 2026 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments on the last calendar day of each month with the first monthly installment occurring on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001193125-25-204935 · ownership.xml · derivative · entry 7

Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner

Vida Ventures III, L.P. · CIK 0001855504 · 10% owner

Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner

Belldegrun Arie · CIK 0001296549 · 10% owner

Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vida Ventures III-A, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,262 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.

F4 · ownership.nature: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.

SEC source: 0001193125-25-204935 · ownership.xml · derivative · entry 6

Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner

Vida Ventures III, L.P. · CIK 0001855504 · 10% owner

Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner

Belldegrun Arie · CIK 0001296549 · 10% owner

Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vida Ventures III, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 547,648 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.

F2 · ownership.nature: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee").

F3 · ownership.nature: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.

SEC source: 0001193125-25-204935 · ownership.xml · nonDerivative · entry 4

Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner

Vida Ventures III, L.P. · CIK 0001855504 · 10% owner

Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner

Belldegrun Arie · CIK 0001296549 · 10% owner

Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vida Ventures III-A, L.P.

Disclosed balance after: 2,029

F4 · ownership.nature: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.

SEC source: 0001193125-25-204935 · ownership.xml · nonDerivative · entry 3

Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner

Vida Ventures III, L.P. · CIK 0001855504 · 10% owner

Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner

Belldegrun Arie · CIK 0001296549 · 10% owner

Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vida Ventures III, L.P.

Disclosed balance after: 880,214

F2 · ownership.nature: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee").

F3 · ownership.nature: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.

SEC source: 0001193125-25-204935 · ownership.xml · nonDerivative · entry 2

Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner

Vida Ventures III, L.P. · CIK 0001855504 · 10% owner

Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner

Belldegrun Arie · CIK 0001296549 · 10% owner

Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vida Ventures III-A, L.P.

Disclosed balance after: 1,262

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.

F1 · price: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.

F4 · ownership.nature: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.

SEC source: 0001193125-25-204935 · ownership.xml · nonDerivative · entry 1

Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner

Vida Ventures III, L.P. · CIK 0001855504 · 10% owner

Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner

Belldegrun Arie · CIK 0001296549 · 10% owner

Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vida Ventures III, L.P.

Disclosed balance after: 547,648

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.

F1 · price: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.

F2 · ownership.nature: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee").

F3 · ownership.nature: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.

SEC source: 0002015536-25-000007 · form4-09162025_100907.xml · derivative · entry 4

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 686,138 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F1 · price: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F2 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0002015536-25-000007 · form4-09162025_100907.xml · nonDerivative · entry 3

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Deep Track Special Opportunities Fund, LP

Disclosed balance after: 666,666

F3 · ownership.nature: Represents securities held by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP is the investment manager of Deep Track Special Opportunities Fund LP. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0002015536-25-000007 · form4-09162025_100907.xml · nonDerivative · entry 2

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,686,138

F2 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0002015536-25-000007 · form4-09162025_100907.xml · nonDerivative · entry 1

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 686,138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F2 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0001726334-25-000003 · form4-09162025_040904.xml · derivative · entry 3

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 411,681 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F4 · shares: Consists of (i) 6,362,625 shares of our redeemable convertible preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 3,637,375 shares of our redeemable convertible preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.

F1 · price: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F2 · derivative.underlying_shares: Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.

SEC source: 0001726334-25-000003 · form4-09162025_040904.xml · nonDerivative · entry 2

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,411,681

F3 · ownership.nature: Consists of (i) 636,263 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 363,737 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.

SEC source: 0001726334-25-000003 · form4-09162025_040904.xml · nonDerivative · entry 1

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 411,681

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F2 · ownership.nature: Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.

SEC source: 0001609805-25-000006 · form4-09162025_040901.xml · derivative · entry 3

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 411,681 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F4 · shares: Consists of (i) 6,362,625 shares of our redeemable convertible preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 3,637,375 shares of our redeemable convertible preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.

F1 · price: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F2 · derivative.underlying_shares: Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.

SEC source: 0001609805-25-000006 · form4-09162025_040901.xml · nonDerivative · entry 2

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,411,681

F3 · ownership.nature: Consists of (i) 636,263 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 363,737 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.

SEC source: 0001609805-25-000006 · form4-09162025_040901.xml · nonDerivative · entry 1

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 411,681

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F2 · ownership.nature: Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.

SEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 11

PRENSKY ZACHARY · CIK 0001167585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,449

Underlying: Common Stock · 22,449 shares

Expires 2035-09-09

F5 · derivative.exercise_date: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 10

PRENSKY ZACHARY · CIK 0001167585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,787

Underlying: Common Stock · 53,787 shares

Expires 2034-06-26

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F4 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 9

PRENSKY ZACHARY · CIK 0001167585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 53,787 shares

Expires 2034-06-26

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F4 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 8

PRENSKY ZACHARY · CIK 0001167585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,929

Underlying: Common Stock · 17,929 shares

Expires 2033-08-24

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 7

PRENSKY ZACHARY · CIK 0001167585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,929 shares

Expires 2033-08-24

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 6

PRENSKY ZACHARY · CIK 0001167585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,255

Underlying: Common Stock · 1,255 shares

Expires 2030-08-30

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 5

PRENSKY ZACHARY · CIK 0001167585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,255 shares

Expires 2030-08-30

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 4

PRENSKY ZACHARY · CIK 0001167585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 896

Underlying: Common Stock · 896 shares

Expires 2029-12-22

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 3

PRENSKY ZACHARY · CIK 0001167585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 896 shares

Expires 2029-12-22

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 2

PRENSKY ZACHARY · CIK 0001167585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,944

Underlying: Common Stock · 3,944 shares

Expires 2028-11-13

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 1

PRENSKY ZACHARY · CIK 0001167585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,944 shares

Expires 2028-11-13

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-024450 · form4-09122025_060915.xml · derivative · entry 1

Kane William P Jr · CIK 0001813937 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,449

Underlying: Common Stock · 22,449 shares

Expires 2035-09-09

F1 · derivative.exercise_date: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024452 · form4-09122025_060919.xml · derivative · entry 1

Hemrajani Rekha · CIK 0001771213 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,449

Underlying: Common Stock · 22,449 shares

Expires 2035-09-09

F1 · derivative.exercise_date: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024451 · form4-09122025_060917.xml · derivative · entry 1

Luse Rebecca · CIK 0002031342 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,449

Underlying: Common Stock · 22,449 shares

Expires 2035-09-09

F1 · derivative.exercise_date: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024446 · form4-09122025_060909.xml · derivative · entry 5

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,449

Underlying: Common Stock · 22,449 shares

Expires 2035-09-09

F4 · derivative.exercise_date: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024446 · form4-09122025_060909.xml · derivative · entry 4

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,585

Underlying: Common Stock · 3,585 shares

Expires 2034-06-05

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on January 31, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024446 · form4-09122025_060909.xml · derivative · entry 3

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,585 shares

Expires 2034-06-05

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on January 31, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024446 · form4-09122025_060909.xml · derivative · entry 2

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,929

Underlying: Common Stock · 17,929 shares

Expires 2034-03-03

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024446 · form4-09122025_060909.xml · derivative · entry 1

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,929 shares

Expires 2034-03-03

F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-024449 · form4-09122025_060913.xml · derivative · entry 7

RUFFOLO ROBERT R · CIK 0001187308 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,449

Underlying: Common Stock · 22,449 shares

Expires 2035-09-09

F4 · derivative.exercise_date: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date.